NCM
AVNS

Narwhal Capital Management’s Avanos Medical AVNS Stock Holding History

Narwhal Capital Management’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-14,225
Closed -$641K – 148
2017
Q3 		$641K Buy
+14,225
New +$607K 0.16% 110

Other funds holding AVNS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Narwhal Capital Management's AVNS Position: Q4 2017 in Review

Narwhal Capital Management sold out of Avanos Medical (AVNS) in Q4 2017, closing a stake of 14,225 shares — an estimated $641K sold.

Narwhal Capital Management first reported a position in AVNS in Q3 2017 and held it in 1 quarter. The position peaked at $641K in Q3 2017. 350 funds tracked by Wall St. Rank hold AVNS as of Q4 2017.

  • Narwhal Capital Management reported no remaining Avanos Medical position as of Q4 2017 after selling out during the quarter.
  • Narwhal Capital Management sold 14,225 Avanos Medical shares in Q4 2017, an estimated $641K.
  • Narwhal Capital Management first reported a position in Avanos Medical in Q3 2017 and held it in 1 quarter.
  • Narwhal Capital Management's Avanos Medical position peaked at $641K in Q3 2017.
  • 350 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2017.

Based on Narwhal Capital Management's 13F filing for Q4 2017, filed 23 Jan 2018.